DelveInsight’s “Dysmenorrhea Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dysmenorrhea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dysmenorrhea Market Forecast
Some of the key facts of the Dysmenorrhea Market Report:
-
The Dysmenorrhea market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In May 2024, TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare and incurable diseases, announced positive topline results from its Phase 2a clinical trial of Merigolix. This oral gonadotropin-releasing hormone (GnRH) receptor antagonist was tested in patients with moderate to severe endometriosis-associated pain. The trial successfully met its primary endpoint, showing a statistically significant reduction in dysmenorrhea scores compared to placebo across all three dosage groups (120mg p=0.044, 240mg p=0.001, 320mg p<0.001).
-
In 2023, the United States held the largest market share for dysmenorrhea, exceeding USD 5 billion, followed by Japan, the EU4 countries, and the UK.
-
In the United States, an estimated 52 million cases of primary dysmenorrhea and 6.8 million cases of secondary dysmenorrhea were reported in 2023.
-
In 2023, Germany recorded the highest number of dysmenorrhea cases among the EU4 countries, with approximately 13 million cases, while Spain had the lowest, at around 8 million cases.
-
Dysmenorrhea affects 50–90% of adolescent girls and women of reproductive age, making it a major cause of absenteeism. Around 25–35% experience severe pain.
-
Primary dysmenorrhea typically starts 6–12 months after menarche, aligning with the onset of ovulatory cycles, and commonly recurs with each menstrual cycle.
-
Relugolix monotherapy was shown to alleviate pelvic pain in women with endometriosis. When combined with estradiol/norethisterone acetate, it helped prevent relugolix-induced bone mineral density loss. Both the FDA and EMA have approved the fixed-dose combination of relugolix/estradiol/norethisterone (MYFEMBREE/RYEQO).
-
Key Dysmenorrhea Companies: ObsEva SA, Fuji Pharma’s, Bayer, Juniper Pharmaceuticals, Inc., Nobelpharma, Laboratorios Andromaco S.A., Boehringer Ingelheim, Organon and Co, Pfizer, Duramed Research, Vantia Ltd, Lianyungang Kanion Group, Ltd., Jiangsu Kanion Pharmaceutical Co, Isifer AB, AbbVie, GlaxoSmithKline, and others
-
Key Dysmenorrhea Therapies: Yselty, FSN-013, Acetaminophen, Lidocaine, NPC-16, Meloxicam, EE20/DRSP(BAY86-5300), Meloxicam, Etoricoxib, piroxicam, levonorgestrel, VA111913, Kanion Capsule, KYG0395, Lignocaine, Elagolix, sumatriptan succinate, and others
-
The Dysmenorrhea epidemiology based on gender analyzed that more than two-thirds of dysmenorrhea patients reported moderate-to-severe pain
-
The Dysmenorrhea market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dysmenorrhea pipeline products will significantly revolutionize the Dysmenorrhea market dynamics.
Dysmenorrhea Overview
In medicine, painful menstrual cycles are referred to as dysmenorrhea, or, to put it more simply, "menstrual cramps." Two types of dysmenorrhea can be distinguished: Dysmenorrhea in two stages: primary and secondary.
Get a Free sample for the Dysmenorrhea Market Report
https://www.delveinsight.com/report-store/dysmenorrhea-market
Dysmenorrhea Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Dysmenorrhea Epidemiology Segmentation:
The Dysmenorrhea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Dysmenorrhea
-
Prevalent Cases of Dysmenorrhea by severity
-
Gender-specific Prevalence of Dysmenorrhea
-
Diagnosed Cases of Episodic and Chronic Dysmenorrhea
Download the report to understand which factors are driving Dysmenorrhea epidemiology trends @ Dysmenorrhea Epidemiology Forecast
Dysmenorrhea Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dysmenorrhea market or expected to get launched during the study period. The analysis covers Dysmenorrhea market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dysmenorrhea Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Dysmenorrhea Therapies and Key Companies
-
Yselty: ObsEva SA
-
FSN-013: Fuji Pharma’s
-
Acetaminophen: Bayer
-
Lidocaine: Juniper Pharmaceuticals, Inc.
-
NPC-16: Nobelpharma
-
Meloxicam: Laboratorios Andromaco S.A.
-
EE20/DRSP(BAY86-5300): Bayer
-
Meloxicam: Boehringer Ingelheim
-
Etoricoxib: Organon and Co
-
piroxicam: Pfizer
-
levonorgestrel: Duramed Research
-
VA111913: Vantia Ltd
-
Kanion Capsule: Lianyungang Kanion Group, Ltd.
-
KYG0395: Jiangsu Kanion Pharmaceutical Co
-
Lignocaine: Isifer AB
-
Elagolix: AbbVie
-
sumatriptan succinate: GlaxoSmithKline
Discover more about therapies set to grab major Dysmenorrhea market share @ Dysmenorrhea Treatment Market
Dysmenorrhea Market Strengths
-
Rising prevalence of dysmenorrhea which is attributed to changing lifestyle, addiction to smoking and alcohol, hormonal changes and physical and mental stress will substantially contribute to high growth of the market.
Dysmenorrhea Market Opportunities
-
Long term use of current treatment options is not recommended as these options are associated with significant side effects such as loss in bone density seen with hormonal agents; hence there is still scope for long-term safe and effective treatment options.
Scope of the Dysmenorrhea Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Dysmenorrhea Companies: ObsEva SA, Fuji Pharma’s, Bayer, Juniper Pharmaceuticals, Inc., Nobelpharma, Laboratorios Andromaco S.A., Boehringer Ingelheim, Organon and Co, Pfizer, Duramed Research, Vantia Ltd, Lianyungang Kanion Group, Ltd., Jiangsu Kanion Pharmaceutical Co, Isifer AB, AbbVie, GlaxoSmithKline, and others
-
Key Dysmenorrhea Therapies: Yselty, FSN-013, Acetaminophen, Lidocaine, NPC-16, Meloxicam, EE20/DRSP(BAY86-5300), Meloxicam, Etoricoxib, piroxicam, levonorgestrel, VA111913, Kanion Capsule, KYG0395, Lignocaine, Elagolix, sumatriptan succinate, and others
-
Dysmenorrhea Therapeutic Assessment: Dysmenorrhea current marketed and Dysmenorrhea emerging therapies
-
Dysmenorrhea Market Dynamics: Dysmenorrhea market drivers and Dysmenorrhea market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Dysmenorrhea Unmet Needs, KOL’s views, Analyst’s views, Dysmenorrhea Market Access and Reimbursement
To know more about Dysmenorrhea companies working in the treatment market, visit @ Dysmenorrhea Clinical Trials and Therapeutic Assessment
Table of Contents
1. Dysmenorrhea Market Report Introduction
2. Executive Summary for Dysmenorrhea
3. SWOT analysis of Dysmenorrhea
4. Dysmenorrhea Patient Share (%) Overview at a Glance
5. Dysmenorrhea Market Overview at a Glance
6. Dysmenorrhea Disease Background and Overview
7. Dysmenorrhea Epidemiology and Patient Population
8. Country-Specific Patient Population of Dysmenorrhea
9. Dysmenorrhea Current Treatment and Medical Practices
10. Dysmenorrhea Unmet Needs
11. Dysmenorrhea Emerging Therapies
12. Dysmenorrhea Market Outlook
13. Country-Wise Dysmenorrhea Market Analysis (2020–2034)
14. Dysmenorrhea Market Access and Reimbursement of Therapies
15. Dysmenorrhea Market Drivers
16. Dysmenorrhea Market Barriers
17. Dysmenorrhea Appendix
18. Dysmenorrhea Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
